• Partial BACE1 Inhibition Lowers Amyloid-β Without Synaptic L

  2026-06-17

  Satir et al. (2020) demonstrate that reducing amyloid-β production by partially inhibiting BACE1 can decrease plaque-forming peptides without impairing synaptic transmission in neuronal cultures. These findings highlight a strategy for Alzheimer's disease research that balances efficacy and neural safety, informing the design of future therapeutic studies.

• Hexamethonium Bromide: Decoding Autonomic Ganglia in Hyperte

  2026-06-17

  Explore how Hexamethonium Bromide, a selective antagonist of neuronal-type nicotinic AChR, enables high-resolution dissection of autonomic ganglia’s role in sex-specific hypertension. This article uniquely bridges methodological rigor with mechanistic insights for advanced neuronal signaling pathway research.

• BMN 673 (Talazoparib): Precision Tool for DNA Repair Deficie

  2026-06-16

  BMN 673 (Talazoparib) empowers researchers to dissect DNA repair pathways with unmatched selectivity and potency, making it a premier choice for homologous recombination-deficient cancer studies. This guide translates advanced mechanistic insights into actionable workflows and troubleshooting strategies for maximizing experimental success with APExBIO’s trusted PARP1/2 inhibitor.

• Anlotinib Hydrochloride (SKU C8688): Reliable TKI for Cancer

  2026-06-16

  This article examines real-world laboratory challenges in angiogenesis and cell viability assays, illustrating how Anlotinib hydrochloride (SKU C8688) addresses reproducibility, sensitivity, and workflow compatibility. Drawing on peer-reviewed data and the APExBIO product dossier, it guides researchers through practical scenarios to optimize their cancer research protocols.

• Trichostatin A (TSA): Epigenetic Modulation Beyond Oncology

  2026-06-15

  Explore the multifaceted roles of Trichostatin A (TSA) in epigenetic regulation, from cancer inhibition to regenerative biology. This article uniquely unpacks TSA’s mechanistic impact and translational potential, with new insights drawn from recent limb regeneration research.

• MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazoliu

  2026-06-15

  MTT, or 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide, is a benchmark colorimetric reagent for in vitro cell proliferation and metabolic activity measurements. Its reduction by cellular NADH-dependent oxidoreductases forms formazan, directly reflecting cell viability. APExBIO’s high-purity MTT ensures reproducibility and sensitivity in diverse cytotoxicity workflows.

• Dasatinib (BMS-354825): Optimizing Kinase Research Workflows

  2026-06-14

  Dasatinib (BMS-354825) empowers applied research into kinase-driven malignancies with quantifiable, reproducible inhibition of Src and Bcr-Abl signaling. This guide delivers actionable protocols, troubleshooting tips, and workflow enhancements for cancer and EMT studies using APExBIO's trusted Dasatinib reagent.

• BMN 673 (Talazoparib) Potent PARP1/2 Inhibitor: Reliable Sol

  2026-06-13

  This article addresses reproducibility and sensitivity challenges in DNA repair and cytotoxicity assays, illustrating how BMN 673 (Talazoparib) Potent PARP1/2 Inhibitor (SKU A4153) meets the demands of modern cancer research. Practical, evidence-backed insights support the effective use of this selective PARP inhibitor for cell viability, proliferation, and DNA damage response workflows.

• Epigenetic Mcl-1 Targeting and Bcl-2 Inhibition in Glioblast

  2026-06-12

  This study demonstrates that epigenetic suppression of Mcl-1, combined with selective Bcl-2/Bcl-xL inhibition, induces synthetic lethality in glioblastoma models. These findings highlight a rational combinatorial approach to overcoming apoptotic resistance in aggressive brain tumors and suggest new directions for apoptosis pathway research.

• Glabridin-Gold(I) Complex Enhances Antitumor Immunity via Tr

  2026-06-12

  This study introduces a novel glabridin-gold(I) (6d) complex that synergistically targets the TrxR and MAPK pathways to enhance antitumor immune responses in liver cancer. By promoting dendritic cell maturation and reducing immunosuppressive cell populations, 6d demonstrates potential as an adjunct to cancer immunotherapy.

• Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibi

  2026-06-11

  Anlotinib hydrochloride sets a new standard for high-selectivity, nanomolar potency in multi-target tyrosine kinase inhibition—outperforming legacy agents in angiogenesis and ERK pathway studies. This article delivers step-by-step assay guidance, practical troubleshooting, and actionable insights for harnessing Anlotinib’s robust anti-angiogenic activity in advanced cancer research.

• Tivozanib (AV-951): Advancing VEGFR Inhibition in Oncology R

  2026-06-11

  Tivozanib (AV-951) stands out as a second-generation, highly selective VEGFR inhibitor for advanced anti-angiogenic therapy and combination regimens. This guide delivers actionable insights for deploying Tivozanib in cell-based and translational oncology models, emphasizing experimental optimization and troubleshooting to maximize reproducibility and clinical relevance.

• Substance P in Applied Research: Protocols & Troubleshooting

  2026-06-10

  Substance P, a high-purity tachykinin neuropeptide from APExBIO, empowers researchers to dissect pain, inflammation, and neuroimmune mechanisms with precision. This guide delivers actionable protocols, advanced spectral troubleshooting, and workflow enhancements that set Substance P apart in experimental neuroscience and immunology.

• Z-YVAD-FMK: Caspase-1 Inhibitor Workflows for Pyroptosis Res

  2026-06-10

  Z-YVAD-FMK from APExBIO is a benchmark caspase-1 inhibitor enabling precise interrogation of inflammasome signaling, apoptosis, and pyroptosis. This article details experimental workflows, troubleshooting strategies, and actionable insights to maximize reproducibility and impact in applied cell death research.

• EZ Cap™ Cas9 mRNA (m1Ψ): Advancing Genome Editing Precision

  2026-06-09

  EZ Cap™ Cas9 mRNA (m1Ψ) combines Cap1 capping and N1-Methylpseudo-UTP modification to deliver unmatched stability and translation efficiency for genome editing in mammalian systems. This article details optimized experimental workflows, troubleshooting strategies, and the practical impact of recent discoveries in mRNA nuclear export regulation. Discover how this product from APExBIO sets new benchmarks for high-fidelity CRISPR-Cas9 editing.

14582 records 1/973 page Next 12345 下5页 Last page